Sai Life Sciences IPO : Check Open Date, Price, Lot Size & Details |Angel One

IPO Details

Bidding Dates

To be announced

Minimum Investment

To be announced

Price Range

To be announced

Maximum Investment

To be announced

Retail Discount

To be announced

Issue Size

To be announced

Investor category and sub category

Qualified Institutional Buyers | Retail Individual Investors | Non-institutional Investors |

Sai Life IPO Dates

Important dates with respect to IPO allotment and listing

IPO Opening Date

To be announced

IPO Closing Date

To be announced

IPO Allotment Date

To be announced

Initiation of Refunds

To be announced

Credit of Shares

To be announced

Listing Date

To be announced

UPI mandate Cut-Off

To be announced

About Sai Life Sciences IPO

Sai Life Sciences Ltd is set to launch an initial public offering (IPO) of equity shares with a face value of ₹1 each. The IPO includes a fresh issue of shares aggregating up to ₹800 crores and an offer for sale of up to 61,573,120 equity shares.

The offer for sale involves up to 6,454,780 equity shares by Sai Quest Syn Private Limited, up to 45,721,080 equity shares by TPG Asia VII SF Pte Ltd, up to 6,862,260 equity shares by HBM Private Equity India, and up to 2,535,000 equity shares by other shareholders as listed in the draft red herring prospectus.

Additionally, the IPO includes a reservation for employees, constituting a percentage of the post-offer paid-up equity share capital. The precise offer price, premium per share, and percentages of shares will be decided by the company. The net offer will exclude the employee reservation portion and will represent specific percentages of the company's equity share capital after the offer.

The IPO is a significant step for Sai Life Sciences Ltd, providing an opportunity for various stakeholders, including promoter selling shareholders and investor selling shareholders, to participate in the company's growth.

About Sai Life Sciences Limited

Sai Life Sciences Limited is an innovation-focused contract research, development, and manufacturing organisation (CRDMO) that offers end-to-end services across the drug discovery, development, and manufacturing value chain, specifically for small molecule new chemical entities (NCEs). These services cater to global pharmaceutical innovator companies and biotechnology firms.

By combining both contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organisation (CDMO) capabilities, Sai Life Sciences supports clients through various stages of their new drug discovery to commercialisation journey. It operates research laboratories in Watertown, Massachusetts, and Manchester, UK, alongside large-scale research and manufacturing facilities in India.

The company's CRO services include integrated discovery capabilities across biology, chemistry, and drug metabolism and pharmacokinetics (DMPK), with over 140 small molecule discovery programs supported in the last five years. These services have led to Investigational New Drug (IND) filings and commercial drug approvals. Its CDMO services focus on developing and scaling up the production of active pharmaceutical ingredients (APIs) and intermediates for clinical and commercial phases, with a product portfolio of 38 APIs and intermediates used in manufacturing 28 commercial drugs, including seven blockbuster drugs (pharmaceuticals with more than $1 billion in revenue annually in the FY 2023).

During the financial year 2024, Sai Life Sciences served over 280 innovative pharmaceutical companies, including 18 of the top 25 global pharmaceutical companies. With a strategic presence in major innovation hubs, the company has access to the latest research trends and a talented global workforce. Its manufacturing and R&D facilities are globally accredited and supported by a qualified pool of scientists and engineers, with regulatory approvals from agencies like the United States Food and Drug Administration (USFDA) and the Pharmaceuticals and Medical Devices Agency, Japan (PMDA).

The company has increased the use of renewable energy at its facilities and is a member of the Pharmaceutical Supply Chain Initiative (PSCI). From the financial years 2022 to 2024, Sai Life Sciences' total revenue from operations grew at a compound annual growth rate (CAGR) of approximately 29.80%, while its EBITDA grew at a CAGR of 51.32%, reflecting its robust financial performance and growth trajectory.

Industry Outlook:

The global CRO industry is expected to grow from $76.5 billion in 2023 to $126.4 billion by 2028, with a CAGR of 10.6%, driven by increased outsourcing and technological advancements.
The Indian small molecule non-clinical CRO industry is projected to become a $1 billion market by 2028, while the Indian small molecule innovator API CDMO industry is expected to capture over 10% of the global market by 2028. Sai Life Sciences Limited can leverage its strong infrastructure and skilled workforce to attract more clients and ensure continued growth and success.
Shifting geopolitical dynamics, such as the "China plus one" strategy and the Biosecure Act, are driving global pharmaceutical companies to diversify their manufacturing bases. This significantly increases demand for Indian CRDMO services and can benefit companies like Sai Life Sciences Limited.

Sai Life IPO Objectives

The company plans to allocate the net proceeds from the issuance to the following purposes:

The company plans to utilise a significant portion of the net proceeds to repay or prepay existing borrowings amounting to ₹6,000 million.
Up to 25% of the gross proceeds will be allocated towards general corporate purposes, which include operational expenses and strategic initiatives.

Peer Details

As per the DRHP, The following are the listed peers of Sai Life Sciences Limited:

Divi's Laboratories Limited
Suven Pharmaceuticals Limited
Syngene International Limited

How to Apply for Sai Life IPO online?

Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
Locate the IPO Section: Navigate to the 'IPO' section on the platform.
Select Sai Life IPO: Find and select the Sai Life IPO from the list of open IPOs.
Enter the Lot Size: Specify the number of lots you want to bid for.
Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.

How to Check the Allotment Status of the Sai Life IPO?

Steps to check IPO allotment status on Angel One’s app:

Log in to the Angel One app
Go to the individual order details page of the IPO that you had applied for.
Check the IPO allotment status. As such, Angel One will notify you of your IPO allotment status via push notification, email, and SMS.

Contact Details of Sai Life Sciences IPO

Registered office: Plot No.DS-7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Medchal–Malkajgiri District, Hyderabad 500078, Telangana, India
Phone: +9140 6815 6000
E-mail: investors@sailife.com

IPO Financials

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Revenue from Operations (in ₹ million)	14,651.78	12,171.39	8,695.93
Profit After Tax (PAT) (in ₹ million)	828.09	99.89	62.26
Cash & Cash Equivalents (in ₹ million)	119.69	355.29	1,157.75
Return on Net Worth (%)	8.49	1.12	0.71
Earnings Per Share (“EPS”) (%)	4.57	0.55	0.35
EBITDA (in ₹ million)	3,001.15	1,822.33	1,310.63

Know before investing

Strengths

Sai Life Sciences Limited boasts a diverse portfolio of commercial and under-development molecules, including drugs and APIs in various clinical trial phases.
The fastest-growing Indian CRDMO among listed peers, showing strong revenue and profitability growth from 2022 to 2024.
The company has fast-growing integrated discovery capabilities, focusing on biology, chemistry, and DMPK services, which are attracting an increasing number of customers.
Sai Life Sciences Limited has long-standing relationships with a diverse base of existing and new customers, including 18 out of the top 25 pharmaceutical companies.
The company's modern R&D infrastructure and strong regulatory track record support its capabilities in providing end-to-end solutions and maintaining high-quality standards.

Risks

The company's financial performance is heavily reliant on securing business from biotechnology and pharmaceutical customers, making it vulnerable to industry trends and uncertainties beyond its control.
The company's success depends on its research and development activities, which are costly, time-consuming, and have a low success rate. If outcomes are not achieved, future growth might be at risk.
Sai Life Sciences Limited is subject to extensive government regulation; failure to obtain, maintain, or renew necessary permits and approvals could adversely impact its operations and financial health.
Failing to meet customer standards during audits and inspections could harm the company's reputation, leading to the termination of ongoing projects and potential financial losses.
Delays or interruptions in manufacturing could hinder the company's ability to meet customer demand.
Losing key customers or large contracts could materially and adversely impact Sai Life Sciences Limited's business, financial condition, and operational results.